AstraZeneca agrees to lower drug prices for Medicaid under Trump administration deal

WASHINGTON — WASHINGTON (AP) — AstraZeneca on Friday grew to become the second main pharmaceutical producer to announce it had agreed to decrease the price of prescribed drugs for Medicaid beneath a deal struck with the Trump administration that prevented its threats of steep tariffs.

President Donald Trump made the announcement within the Oval Workplace with AstraZeneca CEO Pascal Soriot, who stated that in powerful negotiations to achieve a deal, Trump and his staff of officers had “actually stored me up at night time.”

Underneath the settlement, AstraZeneca will cost most-favored-nation pricing to Medicaid, whereas guaranteeing such pricing on newly launched medicine, Trump stated. That includes matching the bottom worth provided in different developed nations.

“For a few years, People have paid the best costs on the earth for prescribed drugs, by far,” Trump stated, including that the brand new deal might minimize costs to “the bottom worth wherever on the earth. That’s what we get.”

AstraZeneca’s deal follows an identical settlement Pfizer introduced late final month. Advocates have usually praised the administration’s efforts to chop drug costs, although some have expressed considerations that an excessive amount of onus is being positioned on the producers to decrease prices with out implementing U.S. coverage safeguards to make sure such outcomes.

Each agreements, nonetheless, construct on an govt order Trump signed in Might that set a deadline for drugmakers to electively decrease costs or face new limits on what the federal government pays. Trump had instructed {that a} sequence of offers with drug corporations would subsequently be coming.

“The tariffs have been an enormous motive he got here right here,” Trump stated of Soriot.

Cambridge, United Kingdom-based AstraZeneca makes a variety of most cancers remedies. Its merchandise embrace the lung most cancers drug Tagrisso; Lynparza, an oral remedy for ovarian most cancers, and Calquence, which treats continual lymphocytic leukemia.

These medicine introduced in a complete of greater than $7.5 billion in U.S. gross sales final yr.

AstraZeneca introduced Thursday that it will spend $4.5 billion on a brand new manufacturing plant close to Charlottesville, Virginia, and its Republican governor, Glenn Youngkin, spoke throughout Friday’s Oval Workplace announcement to cheer groundbreaking on the brand new facility.

The drugmaker stated that mission was the centerpiece of $50 billion in investments the corporate plans to make within the U.S. by 2030.

AstraZeneca stated it plans to achieve $80 billion in whole income by then, half of which will likely be generated in the USA.

Trump predicted the funding’s may result in 3,600 jobs domestically “simply to start with.”

One of many AstraZeneca medicine was already topic to cost reductions resulting from a Medicare negotiating technique carried out beneath President Biden. Nonetheless, Trump insisted that Democrats should not “get credit score” and instructed the get together’s key leaders might attempt.

The bulletins got here months after AstraZeneca stated it was scrapping plans to broaden a vaccine manufacturing plant in its dwelling nation. The corporate blamed a number of elements, together with diminished authorities monetary help.

The Trump administration has put up a touchdown web page for its new web site, TrumpRX.gov, the place folks will be capable to purchase medicine instantly from producers, in response to officers. Each Pfizer and AstraZeneca will provide drugs via the location, in response to the administration.

The web site’s touchdown web page options two very massive footage of Trump and a promise that the location is “Coming Quickly” in January 2026.

It says on the backside of the web page that the location was “Designed in DC by The Nationwide Design Studio,” the brand new authorities web site design hub that Trump created by govt order in August, which is being led by Airbnb co-founder Joe Gebbia.

___

Related Press writers Tom Murphy and Michelle L. Value contributed to this report.